PE Tech Report


Like this article?

Sign up to our free newsletter

Kramer Laboratories to acquire Nizoral from Janssen Pharmaceutica

Kramer Laboratories (Kramer), a marketer of over-the-counter (OTC) foot care and specialty cough products, has acquired Nizoral, an anti-dandruff shampoo brand sold in North America and Latin America, from Janssen Pharmaceutica NV (a member of the Johnson & Johnson family of companies).

Kramer is a portfolio company of Avista Capital Partners (Avista), a healthcare-focused private equity firm, and Dana Holdings, a consumer healthcare-focused private investment group.
Rick Kornhauser, Chief Executive Officer of Kramer, says: “We are delighted to add Nizoral, an iconic OTC brand, to the Kramer portfolio. With over a 25 year history, Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care. This acquisition also significantly enhances our financial profile, adding meaningful scale, growth and profitability to our company. We look forward to building upon Nizoral’s strong brand heritage and continuing to grow the brand through investment and brand support.”
David Burgstahler, President and Co-Managing Partner of Avista, adds: “This is a transformative acquisition for Kramer, one that not only adds an exceptional brand to the portfolio, but also establishes Kramer as a leading OTC consumer healthcare platform of scale. We are excited about Kramer’s future prospects and are committed to supporting the company’s continued development and expansion.”
Ropes & Gray LLP acted as legal counsel to Avista.

Like this article? Sign up to our free newsletter